Symbols

ACXP

Acurx·NASDAQ

--(--)

ACXP fundamentals

ACXP Q4 2025 Earnings

Acurx (ACXP) released its earnings on Mar 12, 2026: revenue was 0 (YoY --), met estimates; EPS was 0 (YoY +100.00%), beat estimates.

Revenue / YoY

EPS / YoY

+100.00%

Report date

Mar 12, 2026

ACXP Earnings Call Summary for Q4,2025

Breakthrough rCDI Trial Launched: 20-patient pilot to evaluate ibezapolstat as single-agent treatment for recurrent CDI, with potential Phase III if successful.
Phase II Results Validate Efficacy: 96% cure rate with no recurrences, microbiome-sparing properties demonstrated.
Financial Strength Improved: $7.6M cash, 67% R&D expense reduction, 27% G&A decline.
Patent Protection Extended: Pol IIIC inhibitor patent extended to 2039.
FDA Regulatory Shift Potential: One-trial requirement could streamline broader CDI approval.
Government Interest: U.S.-based manufacturing and stockpiling potential for public health use.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Acurx (ACXP) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Acurx (ACXP)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Acurx (ACXP)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Acurx (ACXP)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown